Most Read

The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for

The companies are seeking approval for the antibody to treat adult patients with prurigo nodularis, which is a chronic inflammatory skin disease that causes extreme itch and skin

Under the collaboration, the company will use its AI drug discovery platform along with Denali Therapeutics’ expertise across the blood-brain barrier (BBB) and neurodegeneration for identifying therapeutically relevant

Anthracyclines just as doxorubicin are the initial treatment of choice for TNBC. Although doxorubicin has reduced breast cancer mortality significantly, it is linked with a dose-dependent cumulative and

Castle Creek is a portfolio company of Paragon Biosciences, which took part in this preferred stock financing. This financing round saw continued support from Fidelity Management & Research

Biliary tract cancer, which is also called as cholangiocarcinoma, is an extremely rare and hard to treat cancer. It impacts more than 2,000 people in the UK annually

Zavegepant nasal spray is claimed to be the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation for the acute treatment of migraine in

The positive opinion for use of Cosentyx either alone or in combination with methotrexate has been given for the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA)

Proceeds from the financing round will be used by the company to advance Inceptor Bio’s CAR-T lead programme to a Phase I clinical trial as well as continue